礼来公司（LLY）内部人士在股价暴跌后大举买入，释放信心信号——尽管市场对近期药物试验结果反应消极。
上周四（8月7日），该公司股价因口服GLP-1候选药物orforglipron三期ATTAIN-1试验的中期数据不及预期而重挫约14%，创二十多年来最大单日跌幅。
但礼来管理层并未袖手旁观。在其股价重挫之后，该公司首席执行官David Ricks以均价644.77美元购入约1600股（价值100万美元），首席科学官Dan Skovronsky以每股634美元增持1000股。董事Gabrielle Sulzberger与Erik Frywald合计买入1700股，推动内部持股比例上升数个百分点。
虽有部分高管减持（如Ilya Yuffa抛售1300股），但整体呈现“逢低买入”态势。
分析师观点分化。部分认为这是长期投资者难得的买入机会，另一派则警告在更明确试验数据出炉前上行空间有限。
当前礼来内部人士正以实际行动押注，意味着他们认为市场对中期数据的抛售反应过度。分析师认为，礼来公司更广阔的增长动能终将稳定市场情绪。
责任编辑：张俊 SF065
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.